Patents by Inventor Michael Dewain Kalos

Michael Dewain Kalos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD137 ANTIBODIES
    Publication number: 20230279134
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Application
    Filed: November 1, 2022
    Publication date: September 7, 2023
    Inventors: Christopher Carl FRYE, Michael Dewain KALOS, Helen KOTANIDES, Stephanie Lynn SANDEFUR
  • Anti-CD137 antibodies
    Patent number: 11512134
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: November 29, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Christopher Carl Frye, Michael Dewain Kalos, Helen Kotanides, Stephanie Lynn Sandefur
  • Checkpoint inhibitor bispecific antibodies
    Patent number: 11203640
    Abstract: The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human PD-1, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: December 21, 2021
    Assignees: Eli Lilly and Company, Zymeworks Inc.
    Inventors: Michael Dewain Kalos, Yiwen Li, Dale Lincoln Ludwig, Yang Shen, Igor Edmondo Paolo D'Angelo, Gregory D Plowman
  • ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIES
    Publication number: 20210054089
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with anti-human PD-1 antibodies, chemotherapy, and ionizing radiation.
    Type: Application
    Filed: March 15, 2019
    Publication date: February 25, 2021
    Inventor: Michael Dewain KALOS
  • Anti-CD137 antibodies
    Patent number: 10906983
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and is useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: February 2, 2021
    Assignee: ELI LILLY AND COMPANY
    Inventors: Christopher Carl Frye, Michael Dewain Kalos, Helen Kotanides, Stephanie Lynn Sandefur
  • ANTI-CD137 ANTIBODIES
    Publication number: 20200377607
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Application
    Filed: July 25, 2018
    Publication date: December 3, 2020
    Inventors: Christopher Carl FRYE, Michael Dewain KALOS, Helen KOTANIDES, Stephanie Lynn SANDEFUR
  • ANTI-CD137 ANTIBODIES
    Publication number: 20200157234
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Application
    Filed: January 23, 2020
    Publication date: May 21, 2020
    Inventors: Christopher Carl FRYE, Michael Dewain KALOS, Helen KOTANIDES, Stephanie Lynn SANDEFUR
  • Checkpoint Inhibitor Bispecific Antibodies
    Publication number: 20190010232
    Abstract: The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human PD-1, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Application
    Filed: July 9, 2018
    Publication date: January 10, 2019
    Inventors: Michael Dewain Kalos, Yiwen Li, Dale Lincoln Ludwig, Yang Shen, Igor Edmondo Paolo D'Angelo, Gregory D Plowman